Table 2

Changes from baseline in CT and 18F-FLT PET parameters according to confirmed treatment response

All subjects,
n=25
Non-progressive disease,
n=16
Progressive disease,
n=9
P value*
Changes between baseline and week 2
 ΔSUVmax0-2, %6.0 (−58.3 to 120.2)2.1 (−58.3 to 50.9)16.8 (−34.8 to 120.2)0.075
 ΔPTV0-2, %29.0 (−90.7 to 813.2)12.5 (−90.7 to 241.9)101.3 (−27.0 to 813.2)0.066
 ΔTLP0-2, %31.9 (−94.8 to 821.3)12.7 (−94.8 to 223.2)81.6 (−15.9 to 821.3)0.045
All subjects,
n=22
Non-progressive disease,
n=16
Progressive disease,
n=6
P value*
Changes between baseline and week 6
 ΔSUVmax0-6, %−3.4 (-72.3 to 88.1)−17.5 (-72.3 to 17.3)26.3 (-34.8 to 88.1)0.020
 ΔPTV0-6, %−31.2 (−96.9 to 2528.1)−54.7 (−96.9 to 67.1)95.0 (−23.9 to 2528.2)0.0017
 ΔTLP0-6, %−24.9 (−97.1 to 3075.2)−58.1 (−97.1 to 66.8)123.2 (−19.2 to 3075.2)0.0022
  • *P values compare the non-progressive and progressive disease groups.

  • 18F-FLT, 3′-deoxy-3′-[18F]-fluorothymidine; PET, positron emission tomography; PTV, proliferative tumor volume; SUV, standardized uptake value; TLP, total lesion proliferation.